BioCentury
ARTICLE | Company News

Tensha Therapeutics, Roche deal

January 18, 2016 8:00 AM UTC

Roche will acquire Tensha for $115 million in cash plus up to $420 million in undisclosed clinical and regulatory milestones. Tensha’s TEN-010, a small molecule bromodomain inhibitor that is selectiv...